Literature DB >> 33491524

Level of evidence for FDA drug approvals in pivotal clinical trials of hematological malignancies.

Samer Al Hadidi1, Carlos Almeida Ramos1.   

Abstract

Entities:  

Mesh：

Year:  2021        PMID： 33491524      PMCID： PMC8928596          DOI： 10.1080/10428194.2021.1876872

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN： 1026-8022


× No keyword cloud information.
  6 in total

1.  Shortcomings in the clinical evaluation of new drugs: acute myeloid leukemia as paradigm.

Authors:  Roland B Walter; Frederick R Appelbaum; Martin S Tallman; Noel S Weiss; Richard A Larson; Elihu H Estey
Journal:  Blood       Date:  2010-06-10       Impact factor: 22.113

2.  Cancer Drugs Approved on the Basis of a Surrogate End Point and Subsequent Overall Survival: An Analysis of 5 Years of US Food and Drug Administration Approvals.

Authors:  Chul Kim; Vinay Prasad
Journal:  JAMA Intern Med       Date:  2015-12       Impact factor: 21.873

3.  The power of comparative studies.

Authors:  Roland B Walter; Elihu H Estey
Journal:  Leuk Res       Date:  2008-11-05       Impact factor: 3.156

4.  Cancer statistics, 2020.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2020-01-08       Impact factor: 508.702

5.  Diversity of participants in clinical trials in an academic medical center: the role of the 'Good Study Patient?'.

Authors:  Galen Joseph; Daniel Dohan
Journal:  Cancer       Date:  2009-02-01       Impact factor: 6.860

6.  Participation of African American Persons in Clinical Trials Supporting U.S. Food and Drug Administration Approval of Cancer Drugs.

Authors:  Samer Al Hadidi; Martha Mims; Courtney Nicole Miller-Chism; Rammurti Kamble
Journal:  Ann Intern Med       Date:  2020-06-23       Impact factor: 25.391
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.